INmune Bio has signed a Master Services Agreement with Uniphar to establish a global framework for distributing and commercializing Ebstrocel™, its cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Initially focusing on named-patient access in select European and MENA countries, this approach allows physicians to request the therapy for individual patients before full regulatory approval. The partnership leverages Uniphar's established infrastructure to enable efficient international expansion and prepare for broader commercialization as regulatory approvals progress. This move marks a key step toward making Ebstrocel™ available to patients globally.
INmune Bio's strategic agreement with Uniphar for global commercialization of Ebstrocel™ provides context for healthcare sector interest. For readers following the health sector, here is Pluang's market snapshot as of Oct 21, 2026 17:11 WIB: Among 150 priced US health stocks, 77 rose and 61 fell today. Notable movers include HALO at USD 127.43 with a 1-day change of +2.46%, ABT at USD 101.00 with a 1-day change of -1.65% and Pluang order activity showing 67% Buy, and HRTX at USD 0.36 with a 1-day change of +1.55% and a typical hold time of 37 days.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
